Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taisho Pharmaceutical Buys Back Shanghai Dazhengli Health Care Shares

This article was originally published in PharmAsia News

Executive Summary

Japanese firm Taisho Pharmaceutical, a majority stakeholder of Shanghai Dazhengli Health Care, has purchased the latter's 15 percent shares held by Guan Shen Yuan (Group) at RMB 14.7994 million. Taisho Pharmaceutical, the world's leading OTC manufacturer, set up Shanghai Dazhengli Health Care in 1997 to promote and sell its Libogen products in China. Shanghai Dazhengli can output more than 20 million bottles of Lipovitan D nutrient drink annually, with China being Taisho's best overseas market. Taisho has been trying to expand its production capacity and sales in the country, with major markets extending from Shanghai to the north, northeast and south of China. Analysts observe that the buy-back indicates Taisho's confidence in the market. (Click here for more - Chinese Language)

You may also be interested in...



WHO Prequalifies Celltrion’s Rituximab

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

Medac Will Market Fresenius Kabi’s Adalimumab In Germany

Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.

Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses

Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel